In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids

Clinical and Experimental Immunology

Volumn 131, Issue 1, 2003, Pages 82-89

  Goddard, R V ^a   Prentice, A G ^a   Copplestone, J A ^a   Kaminski, E R ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

B cell chronic lymphocytic leukaemia; Dendritic cells; Fusion; IL 15; Tumour

Indexed keywords

CD83 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 15; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B CELL LEUKEMIA; CELL CULTURE; CELL LYSATE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROFUSION (CELL); FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INHIBITION KINETICS; INTERFERON PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

B-LYMPHOCYTES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL FUSION; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYBRIDOMAS; INTERFERON-ALPHA; INTERLEUKIN-15; LEUKEMIA, B-CELL, CHRONIC; LIPOPOLYSACCHARIDES; POLYNUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037234653     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02047.x     Document Type: Article

References (35)

1. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. Generation in vitro of B-cell chronic lymphocytic leukaemia- proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin Exp Immunol 2001; 126:16-28.
2. van Elsas A, van der Burg SH, van der Minne CE et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stable HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996; 26:1683-9.
3. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of anti-leukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133-42.
4. Eibl B, Ebner S, Duba C et al. Dendritic cells generated from blood precursors of chronic myelogenous leukaemia patients carry the translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997; 20:215-23.
5. +T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91:977-83.
6. Tsai V, Kawashima I, Keogh E, Daly K, Sette A, Cellis E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998; 18:65-75.
7. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001; 112:959-64.
8. Zhou LJ, Tedder T. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995; 154:3821-35.
9. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999; 13:51-63.
10. + dendritic cells. Proc Natl Acad Sci USA 1996; 93:2588-93.
11. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells. J Immunol 1997; 158:2919-25.
12. Verdijk RM, Mutis T, Esendam B et al. Polyriboinosinic polyribocytidylic acid (Poly(I:C) induces stable maturation of functionally active human dendritic cells. J Immunol 1999; 163:57-61.
13. Luft T, Pang KC, Thomas E et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161:1947-53.
14. + T cell responsiveness to antigen. J Immunol 1998; 161:2141-50.
15. Campbell JD, Cook G, Robertson SE et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol 2001; 167:553-61.
16. Reid CDL. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112:874-88.
17. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54:777-85.
18. Yewdell JW, Bennink JR, Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 1988; 239:637-40.
19. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61.
20. Guo Y, Wu M, Chen H et al. Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263:518-20.
21. Stuhler G, Trefzer U, Walden P. Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti-tumour cytotoxic T cells. Adv Exp Med Biol 1998; 451:277-82.
22. Scott-Taylor TH, Pettengell R, Clarke I et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000; 1500:265-79.
23. Jaroszeski MJ, Gilbert R, Fallon PG, Heller R. Mechanically facilitated cell-cell electrofusion. Biophys J 1994; 67:1574-81.
24. Loken MR, Wells DA. Immunofluorescence of surface markers. In: Ormerod MG, ed. Flow cytometry. A practical approach, 2nd edn. Oxford: IRL Press, 1994.
25. Vuillier F, Maloum K, Thomas EK, Jouanne C, Dighiero G, Scott-Algara D. Functional monocyte-derived dendritic cells can be generated in B-CLL. Br J Haematol 2001; 115:831-44.
26. Hersey P. Impediments to successful immunotherapy. Pharmacol Ther 1999; 81:111-9.
27. de Visser K, Kast WM. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 1999; 13:1188-99.
28. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-2003.
29. Kremer JP, Reisbach G, Neri C, Dormer P. B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br J Haemotol 1992; 80:480-7.
30. Chen H, Treweeke AT, West DC et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96:3181-7.
31. Dooms H, Van Belle T, Desmedt M, Rottiers P, Grooten J. Interleukin-15 redirects the outcome of a tolerizing T-cell stimulus from apoptosis to anergy. Blood 2000; 96:1006-12.
32. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med 2000; 6:332-6.
33. Gong J, Nikrui N, Chen et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumour immunity. J Immunol 2000; 165:1705-11.
34. Li LH, Henson ML, Zhao YL, Hui SW. Electrofusion between heterogenous-sized mammalian cells in a pellet: potential applications in drug delivery and hybridoma formation. Biophys J 1996; 71:479-86.
35. Lindner M, Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy. comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur J Clin Invest 2002; 32:207-17.